Skip to main content

Sponsored By

Lilly
Interview with the Innovators
A Dose Escalation Strategy for HR+/HER2− Early Breast Cancer: An Educational Video Series

TRADE Study Insights: A New Approach to Improve Abemaciclib Tolerability in Breast Cancer Care

Videos - Interview with the Innovators
Erica Mayer, MD, MPH
Director, Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
In this second installment, Dr Mayer discusses her insights from the results of the adjuvant TRADE study and how the dose-escalation approach for abemaciclib used in the study can help patients better manage side effects and stay on therapy, ultimately improving outcomes.
Related Items
Improving Abemaciclib Tolerability: Insights From the TRADE Dose-Escalation Study
Jamie Carroll, APRN, CNP, MSN
Videos published on November 12, 2025 in Interview with the Innovators
Managing Abemaciclib Side Effects: Practical Tips for Improving Patient Care
Jamie Carroll, APRN, CNP, MSN
Videos published on November 10, 2025 in Interview with the Innovators
Managing Abemaciclib Toxicity: Proactive Strategies for Improved Patient Outcomes
Heather Moore, PharmD, BCOP, CPP
Videos published on November 5, 2025 in Interview with the Innovators
Insights From the TRADE Study: Optimizing Abemaciclib Dose Escalation for Better Tolerability and Adherence
Heather Moore, PharmD, BCOP, CPP
Videos published on November 3, 2025 in Interview with the Innovators
Optimizing Adjuvant Abemaciclib: Insights From the TRADE Study on Dose Escalation and Tolerability
Erica Mayer, MD, MPH
Videos published on October 24, 2025 in Interview with the Innovators
Importance of Hospital Partnerships for Bispecific Agent Implementation
Laura Bobolts, PharmD, BCOP, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, Yonatan Resnick, PharmD
Videos published on March 21, 2025 in Interview with the Innovators
EHR Implementation of Bispecific Agents for Multiple Myeloma
Laura Bobolts, PharmD, BCOP, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, Yonatan Resnick, PharmD
Videos published on March 13, 2025 in Interview with the Innovators
Total Cost of Care for Bispecific Agents in Multiple Myeloma
Laura Bobolts, PharmD, BCOP, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, Yonatan Resnick, PharmD
Videos published on March 10, 2025 in Interview with the Innovators
Clinical Pathways in Multiple Myeloma
Laura Bobolts, PharmD, BCOP, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, Yonatan Resnick, PharmD
Videos published on February 27, 2025 in Interview with the Innovators
Payer Policy Development for Bispecific Agents in Multiple Myeloma
Laura Bobolts, PharmD, BCOP, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, Yonatan Resnick, PharmD
Videos published on February 19, 2025 in Interview with the Innovators